Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer

BACKGROUND: Peritoneal carcinomatosis (PC) represents an unfavourable prognostic factor for patients with gastric cancer (GC). Intraperitoneal treatment with the bispecific and trifunctional antibody catumaxomab (EpCAM, CD3), in addition to systemic chemotherapy, could improve elimination of PC. MET...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Cancer
Prif Awduron: Knödler, Maren, Körfer, Justus, Kunzmann, Volker, Trojan, Jörg, Daum, Severin, Schenk, Michael, Kullmann, Frank, Schroll, Sebastian, Behringer, Dirk, Stahl, Michael, Al-Batran, Salah-Eddin, Hacker, Ulrich, Ibach, Stefan, Lindhofer, Horst, Lordick, Florian
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group UK 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6070920/
https://ncbi.nlm.nih.gov/pubmed/29988111
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0150-6
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg